Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 310

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

Open access
Inker, Lesley A., Heerspink, Hiddo J. L., Tighiouart, Hocine, Levey, Andrew S., Coresh, Josef, Gansevoort, Ron T., Simon, Andrew L., Ying, Jian, Beck, Gerald J., Wanner, Christoph, Floege, Jürgen, Li, Philip Kam-Tao, Perkovic, Vlado, Vonesh, Edward F., Greene, Tom·2019·Journal of the American Society of Nephrology

Abstract

Significance Statement: Surrogate end points are needed to assess whether treatments are effective in the earlier stages of CKD. Measuring the effects of treatments on GFR decline, which leads to kidney failure, might be one way to identify early benefits of CKD treatments. So far regulators have not approved the use of GFR slope, the difference in the change in GFR between treatment groups over time, as an end point in CKD randomized, controlled trials because they are concerned that small treatment effects on GFR may not translate into meaningful clinical benefits. Using a Bayesian individual patient meta-analysis of 47 studies including 60,620 participants, the authors found, that for sufficiently large studies, treatment effects on GFR slope from baseline and from 3-month follow-up of 0.5–1.0 ml/min per 1.73 m 2/yr strongly predict benefits on clinical end points such as doubling of serum creatinine, GFR<15 ml/min per 1.73 m 2, or ESKD. GFR slope can play a useful role as a surrogate end point for CKD progression in clinical trials. Background: Surrogate end points are needed to assess whether treatments are effective in the early stages of CKD. GFR decline leads to kidney failure, but regulators have not approved using differences in the change in GFR from the beginning to the end of a randomized, controlled trial as an end point in CKD because it is not clear whether small changes in the GFR slope will translate to clinical benefits. Methods: To assess the use of GFR slope as a surrogate end point for CKD progression, we performed a meta-analysis of 47 RCTs that tested 12 interventions in 60,620 subjects. We estimated treatment effects on GFR slope (mean difference in GFR slope between the randomized groups), for the total slope starting at baseline, chronic slope starting at 3 months after randomization, and on the clinical end point (doubling of serum creatinine, GFR<15 ml/min per 1.73 m 2, or ESKD) for each study. We used Bayesian mixed-effects analyses to describe the association of treatment effects on GFR slope with the clinical end point and to test how well the GFR slope predicts a treatment’s effect on the clinical end point. Results: Across all studies, the treatment effect on 3-year total GFR slope (median R 2=0.97; 95% Bayesian credible interval [BCI], 0.78 to 1.00) and on the chronic slope (R 2 0.96; 95% BCI, 0.63 to 1.00) accurately predicted treatment effects on the clinical end point. With a sufficient sample size, a treatment effect of 0.75 ml/min per 1.73 m 2/yr or greater on total slope over 3 years or chronic slope predicts a clinical benefit on CKD progress with at least 96% probability. Conclusions: With large enough sample sizes, GFR slope may be a viable surrogate for clinical end points in CKD RCTs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2019010007

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 310

Metadata

Authors
Inker, L. A., Heerspink, H. J. L., Tighiouart, H., Levey, A. S., Coresh, J., Gansevoort, R. T., Simon, A. L., Ying, J., Beck, G. J., Wanner, C., Floege, J., Li, P. K.-T., Perkovic, V., Vonesh, E. F., & Greene, T.
Venue
Journal of the American Society of Nephrology
Published
2019-07-10
Volume
30
Issue
9
Pages
1735-1745
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2962169757
Cited by
310
References
40
FWCI
5.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1681/asn.2019010007
The paper
Inker, L. A., Heerspink, H. J. L., Tighiouart, H., Levey, A. S., Coresh, J., Gansevoort, R. T., Simon, A. L., Ying, J., Beck, G. J., Wanner, C., Floege, J., Li, P. K.-T., Perkovic, V., Vonesh, E. F., & Greene, T. (2019). GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2019010007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.